Advancing Nose-to-Brain Delivery with Intranasal Platforms

Intranasal Platforms for Nose-to-Brain Delivery

This piece examines the growing scientific and development interest in nose-to-brain delivery for central nervous system (CNS) therapies and explains why delivery system design is becoming an increasingly important part of the discussion. Rather than viewing intranasal administration simply as an alternative route, it frames nose-to-brain delivery as a system-level challenge in which formulation behaviour, device performance, administration conditions, and user handling all influence the outcome. In this context, NeuroSpray™ is introduced as a multi-dose intranasal platform developed for CNS-focused programmes and intended to support more controlled delivery to upper nasal regions associated with olfactory and trigeminal transport.

The Growing Interest in Nose-to-Brain Delivery

Renewed attention to nose-to-brain delivery is being driven by several converging factors. CNS pipelines are expanding, yet many therapies continue to face limitations related to speed of onset, invasiveness, and restricted CNS exposure via conventional routes. In parallel, patients and healthcare systems are placing greater value on non-invasive, rapid, and self-administered treatment options. Advances in the understanding of olfactory and trigeminal transport have also helped reposition nose-to-brain delivery from an academic concept to a more structured development space focused on reproducibility, delivery performance, and evidence generation.

Why Device Design Matters

A central theme is that successful intranasal CNS delivery depends not only on the molecule itself, but also on where and how the dose deposits within the nasal cavity. The olfactory region is small and difficult to access consistently, and deposition can vary significantly according to insertion angle, insertion depth, and user technique. Such variability can complicate the interpretation of programme outcomes, making it harder to distinguish biological effect from inconsistency in administration. For that reason, device performance and administration conditions are presented as being as important as formulation, particularly when the objective is to engage upper nasal regions linked to olfactory and trigeminal transport rather than areas associated primarily with local or systemic absorption.

NeuroSpray™ and the System Approach

Within this scientific framework, NeuroSpray™ is positioned as a multi-dose platform developed specifically for nose-to-brain and CNS-focused programmes rather than for general nasal use. Key design elements highlighted include optimised spray geometry, a nostril stop, and an adapted nozzle diameter, all intended to support delivery to upper nasal regions while reducing variability in insertion and orientation. The platform is also described as including a preservative-free configuration, enabling alignment between device format and programme-specific requirements. More broadly, nose-to-brain development is presented as a nasal-specific system challenge in which formulation behaviour, device performance, and patient use should be considered together from the outset.

Formulation, Human Factors, and Evidence Generation

Successful development in this area depends on more than device mechanics alone. Formulation-device compatibility is an important consideration, particularly because nasal delivery cannot be treated as a simple adaptation of an injectable formulation. Constraints related to mucosal interaction, spray performance, and regional deposition must all be taken into account. Human factors are also emphasized, since handling technique directly affects real-world consistency and therefore influences delivery performance beyond controlled settings. In parallel, imaging and biodistribution studies involving radiolabelled intranasal insulin are referenced as part of a broader evidence-building effort, supporting the view that the delivery approach can influence measurable brain uptake and should be considered when interpreting development outcomes.

Therapeutic Relevance and Future Direction

Nose-to-brain delivery is positioned as particularly relevant where rapid onset, non-invasive administration, and improved CNS access align with high unmet need and realistic development pathways. Examples discussed include neurodegenerative and psychiatric areas, select neurological disorders, and metabolic-CNS concepts such as intranasal insulin for cognitive impairment. At the same time, the field is presented as promising but not yet fully standardised. Future progress is therefore linked to repeatability, evidence quality, and patient-relevant usability. In that setting, NeuroSpray™ is presented not as evidence that nose-to-brain delivery has been fully solved, but as a platform intended to support a longer-term, evidence-building development journey.